BridgeBio Pharma Price to Sales Ratio 2018-2024 | BBIO

Historical PS ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The current P/S ratio for BridgeBio Pharma as of November 01, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
BridgeBio Pharma P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-11-01 25.48 20.74
2024-06-30 25.33 $1.23 20.62
2024-03-31 30.92 $1.23 25.19
2023-12-31 40.37 $0.06 696.58
2023-09-30 26.37 $0.06 440.12
2023-06-30 17.20 $0.04 463.00
2023-03-31 16.58 $0.53 31.30
2022-12-31 7.62 $0.53 14.40
2022-09-30 9.94 $0.61 16.40
2022-06-30 9.08 $0.62 14.65
2022-03-31 10.15 $0.48 20.93
2021-12-31 16.68 $0.48 34.99
2021-09-30 46.87 $0.39 120.65
2021-06-30 60.96 $0.44 138.15
2021-03-31 61.60 $0.07 842.20
2020-12-31 71.11 $0.07 1018.64
2020-09-30 37.52 $0.20 187.36
2020-06-30 32.61 $0.13 248.01
2020-03-31 29.00 $0.36 80.58
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00